Examples of IND Holder in a sentence
Click “Add” to provide the IND number, Drug Name, and IND Holder in a pop‐up window.
Dr. Vedantham (Principal Investigator and IND Holder) will notify the NHLBI Project Officer; the DSMB Executive Secretary; the Washington University Human Research Protection Office; the FDA (fax (800) FDA-1078); Genentech Drug Safety (telephone (650) 225-2232, fax (650) 225-4630 or (650) 225-5288); the ATTRACT Steering Committee, and the Clinical Center investigators of any SAE that is a UP within 7 calendar days of first learning of the event.
The Medical Monitor is responsible for notifying the Principal Investigator (IND Holder) of any changes to the categorizations of serious adverse events and of any concerns regarding the frequency or type of adverse event(s).
Both have upstream transmission service providers (“TSPs”) that are owed money in connection with transmission services that MISO and ERCOT provided to the Debtor.
PennERAOverview or Pending Issue that May Impact Future Reviews: If IND Exempt: Include a note that states this, who did the exemption, and the date of the letter (if done by another Penn internal entity)Penn IND Holder: Should be checked when the University holds the IND.
PennERA• Overview or Pending Issue that May Impact Future Reviews: If IDE Exemption: Include a note that states this, who did the exemption, and the date of the letter (if done by another Penn internal entity)• Penn IND Holder: Should be checked when the University holds the IDE.
Phoenix, AZ 85054 480/301-8000 IND Holder: Study Co-Chairs:Statistician: Drug AvailabilitySupplied Investigational Agents: AZD1775Commercial Agents: Cytarabine (cytosine arabinoside or AraC) √ Study contributor(s) not responsible for patient care.
San Francisco, CA 94080Contact: Dr. Sanjay Gurunathan Contact: Dr. Don FrancisTel/Fax: 1-570-839-6185/0934 Tel/Fax: 1-650-228-7900/7901 Sponsor (Study IND Holder): Local Sponsor Liaison:Robert E.
Non-serious adverse events will be reported annually to FDA via an Annual Report (IND 119474) and to IRB via Continuing Review.The PD (aka Principle Investigator) must immediately report within 24 hours of knowledge of event to the Sponsor (ie, IND Holder, Eben Rosenthal, MD), any serious adverse event, whether or not considered related to study drug.
For example, as far as FDA is concerned, the sponsor is the IND Holder in the case that the study is under IND; and, an agreement for transferring responsibilities is documented with the IND Holder and the partner organization.